Evan Roberts Sells 1,843 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) COO Evan Roberts sold 1,843 shares of the business’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $21.03, for a total value of $38,758.29. Following the sale, the chief operating officer now owns 753,876 shares of the company’s stock, valued at $15,854,012.28. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Evan Roberts also recently made the following trade(s):

• On Tuesday, September 10th, Evan Roberts sold 3,148 shares of Phreesia stock. The shares were sold at an average price of $23.25, for a total value of $73,191.00.

Phreesia Stock Down 2.9 %

NYSE:PHR opened at $19.81 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.77 and a current ratio of 1.77. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of -11.01 and a beta of 0.93. Phreesia, Inc. has a one year low of $12.05 and a one year high of $29.16. The stock has a 50-day simple moving average of $23.30 and a 200 day simple moving average of $22.42.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Wednesday, September 4th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.06. Phreesia had a negative return on equity of 39.34% and a negative net margin of 25.73%. The business had revenue of $102.12 million during the quarter, compared to the consensus estimate of $101.76 million. Sell-side analysts predict that Phreesia, Inc. will post -1.23 EPS for the current fiscal year.

Institutional Trading of Phreesia

Institutional investors have recently added to or reduced their stakes in the business. Capital International Investors boosted its holdings in shares of Phreesia by 221.1% in the 1st quarter. Capital International Investors now owns 2,593,063 shares of the company’s stock valued at $62,052,000 after buying an additional 1,785,463 shares during the period. Champlain Investment Partners LLC acquired a new position in Phreesia in the first quarter valued at approximately $29,941,000. Blair William & Co. IL grew its holdings in shares of Phreesia by 42.6% during the first quarter. Blair William & Co. IL now owns 752,700 shares of the company’s stock valued at $18,012,000 after purchasing an additional 224,950 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Phreesia by 4.4% during the 4th quarter. Vanguard Group Inc. now owns 4,628,441 shares of the company’s stock worth $107,148,000 after purchasing an additional 194,035 shares during the period. Finally, Deerfield Management Company L.P. Series C bought a new stake in shares of Phreesia in the 2nd quarter worth approximately $4,078,000. Institutional investors own 92.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on PHR shares. Canaccord Genuity Group reiterated a “buy” rating and issued a $34.00 target price on shares of Phreesia in a research note on Thursday, September 5th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $23.00 price objective on shares of Phreesia in a research report on Friday, September 27th. DA Davidson reissued a “buy” rating and set a $32.00 target price on shares of Phreesia in a research report on Thursday, September 5th. Truist Financial raised their price target on shares of Phreesia from $29.00 to $31.00 and gave the company a “buy” rating in a report on Friday, September 6th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Phreesia from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Monday, September 9th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $29.42.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.